Abstract
Chronic lymphocytic leukemia (CLL) is a chronic B lymphocyte clonal proliferative disease with a median age at onset of more than 70 years. The clinical manifestations are CD5 and CD19 double positive mature small lymphocytes abnormal aggregation in peripheral blood, bone marrow, spleen and lymph nodes, which cause corresponding clinical symptoms. In recent years, targeted drugs such as CD20 monoclonal antibodies, B cell lymphoma (BCL)-2 inhibitors, Bruton tyrosine kinase inhibitor (BTKi), and allogeneic hematopoietic stem cell transplantation (allo-HSCT) continues to appear, the efficacy of CLL continues to improve. But the case fatality rate of patients with relapsed/refractory CLL remains high. In the era of immune cell therapy, chimeric antigen receptor T cell (CAR-T) immunotherapy achieves specific recognition of CLL cell surface antigen and precise target killing of tumor cells. This article reviews the research of CAR-T immunotherapy in CLL. Key words: Leukemia, lymphocytic, chronic, B-cell; Immunotherapy; Recurrence; Antigens, CD19; Chimeric antigen receptor T-cell
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
